Renaissance Technologies LLC Invests $3.45 Million in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Renaissance Technologies LLC acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 136,588 shares of the biopharmaceutical company's stock, valued at approximately $3,452,000. Renaissance Technologies LLC owned about 0.21% of Celldex Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Invesco Ltd. lifted its position in Celldex Therapeutics by 2.1% in the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock valued at $1,064,000 after purchasing an additional 871 shares during the last quarter. Aristides Capital LLC bought a new stake in Celldex Therapeutics in the 4th quarter valued at about $202,000. ExodusPoint Capital Management LP bought a new stake in shares of Celldex Therapeutics during the 4th quarter worth about $436,000. Cinctive Capital Management LP lifted its stake in shares of Celldex Therapeutics by 140.6% in the 4th quarter. Cinctive Capital Management LP now owns 81,320 shares of the biopharmaceutical company's stock worth $2,055,000 after acquiring an additional 47,523 shares during the period. Finally, Bryce Point Capital LLC bought a new position in shares of Celldex Therapeutics in the fourth quarter valued at approximately $601,000.

Analysts Set New Price Targets

Several brokerages recently commented on CLDX. The Goldman Sachs Group dropped their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target for the company. HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a report on Friday, February 28th. Finally, Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research report on Monday. They issued a "buy" rating and a $64.00 price target on the stock. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Celldex Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $55.30.

Celldex Therapeutics Price Performance

Celldex Therapeutics stock traded up $1.79 during mid-day trading on Monday, hitting $21.36. The company's stock had a trading volume of 999,717 shares, compared to its average volume of 883,354. The firm's 50 day moving average is $19.18 and its 200 day moving average is $23.37. The company has a market cap of $1.42 billion, a PE ratio of -8.31 and a beta of 1.59. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.